Taipei, October 11, 2023 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading player in the Taiwan pharmaceutical industry, is delighted to announce its unaudited consolidated revenue for September 2023, which reached NT$1.1 billion. The company's unaudited consolidated revenue for the third quarter surged to NT$4.573 billion, marking a 3% increase compared to the preceding quarter. Lotus Pharmaceutical's year-to-date consolidated revenue as of the end of September reached NT$13.538 billion, reflecting 18.13% growth year-on-year when compared to the same period in the previous year.
In September, the Asia business segment saw a remarkable 17% year-on-year revenue growth. Taiwan led the way by achieving 46% growth compared to the same period last year. In South Korea, Lotus launched its Postherpetic Neuralgia (PHN) medication, Gabapentin ER 300/600 mg, to the market in mid-September.
The export market revenue performance in September is subject to unique circumstances, making a single-month year-on-year comparison challenging due to the first-time launch shipments for the U.S. blood cancer drug in the previous year, as opposed to the steady quarterly shipments this year. However, the export market witnessed a substantial 14% growth in revenue for the first 9 months of the year compared to the same period last year. This growth is primarily driven by the strong global demand for Lenalidomide and the consistent demand for Buprenorphine/Naloxone in the United States.
Lotus Pharmaceutical has successfully transformed from a local Taiwanese generic pharmaceutical company into a global pharmaceutical platform with a diverse product portfolio, including generic drugs, branded drugs, NCEs, and 505b(2) products. In the future, Lotus will continue to expand its presence in innovative and high-entry-barrier product segments, thereby enhancing its overall operational efficiency.
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. The Company has a recognized best-in-class R&D and manufacturing platform in Asia and has established partnerships in nearly every global market including the U.S., Europe, Japan, China, and Brazil. Lotus runs over 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, with over 250 commercial products. The Company invests in diversified best portfolio consisting of high-barrier oncology, complex generics as well as 505(b)2 and NCE via internal R&D investment and licensing-in partnership, and also strengthens its portfolio competitiveness by adding biosimilar products with support from strategic partners. Its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.
Susan Liao, IR/PR Director
+886 2 2700 5908